Type 2 Diabetes Clinical Trial
Official title:
The Swedish Study on Paleolithic Diet for Type 2 Diabetes
Background Paleolithic diet is a modern dietary regimen based on food eaten during the
Paleolithic (2.5 million-10.000 years before present); lean meats, fish, shellfish, fruits,
vegetables, root vegetables, eggs and nuts. Food that was not eaten during the Paleolithic is
avoided; cereals, dairy products, salt, refined sugar and fat. The rationale for Paleolithic
diet is based on the lack of type 2 diabetes and associated diseases among hunter-gatherer
populations. Our group have previously studied effects of Paleolithic diet in an
observational study in humans, an intervention study in animals and two intervention studies
in patients with type 2 diabetes or lowered glucose tolerance and ischaemic heart disease.
Our intervention studies showed significant improvement of glucose tolerance, HbA1c, blood
lipids, blood pressure, weight, waist circumference and satiety on Paleolithic diet compared
with a Mediterranean-type diet and diabetes diet. Studies by other research groups on healthy
individuals found that Paleolithic diet lowered weight, waist circumference, blood pressure,
PAI-1, blood lipids and ectopic lipid deposition, and also improved glucose tolerance and
insulin sensitivity.
Purpose and aims Our goal is to study effects of Paleolithic diet compared to recommended
diet on risk factors, morbidity and mortality from type 2 diabetes and associated diseases in
a sufficiently large and well executed study to be included in basis for future dietary
recommendations.
Project descriptions SwePaD is a study with an initial 18 month long randomized cross-over
dietary intervention on 150 patients with type 2 diabetes where the whole study population
upon finishing the initial dietary intervention is studied as a cohort for another 5 years.
The initial 18 month long dietary intervention compares 6 months on Paleolithic diet with 6
months on recommended diabetes diet separated by 6 months wash-out period. After the initial
18 month long dietary intervention the study participants are recommended to follow
recommended diabetes diet with implementation of optional elements from a Paleolithic diet
for the remaining 5 years of the study.
The intervention, in the form of diet information, will be given orally and written by the
study participant's own diabetes nurse or doctor, based on similarly designed written
information on the two diets. The same intervention was successfully used in our pilot study.
The study participants will otherwise receive usual treatment.
Power calculations show that 126 participants are needed to obtain significant results with
80% power at the 95% significance level for the primary outcome HbA1c. The pilot study with
the same intervention but slightly healthier participants than the average patient in
Diabetesregistret showed significant results on HbA1C with only 13 participants.
Secondary outcomes are fasting glucose levels, weight, waist circumference, blood pressure,
blood lipids, urinary albumin, diabetes retinopathy, smoking, physical activity,
monofilaments (detection of peripheral neuropathy) and health related quality of life
assessed by the health survey questionnaire SF-36. Primary and secondary outcomes as well as
medication will be registered before and after each intervention diet. Data on primary and
secondary outcomes, morbidity and mortality from type 2 diabetes and associated diseases will
be retrieved for up to five years after participants' completion of the dietary intervention
from the Diabetes register, Cause of Death Register (Dödsorsaksregistret) and the Hospital
Discharge Register (Patientregistret) and compared to expected outcome from a statistical
model based on the Diabetes register (A new model for 5-year risk of cardiovascular disease
Cederholm et al 2011) and/or a matched control group from the Diabetes register.
Participants will be recruited nationwide through information to health care personnel in
primary health care and hospital diabetes clinics and to patient organisations. Participants'
registration, intervention and data gathering will be administered by the participants' own
diabetes nurse or doctor via REDCap, a web based tool for secure electronic data capture
hosted on secure servers with daily back-up by the Library and IKT department of the medical
faculty at Lund University.
Dietary evaluation will be made using four day weighed food records on paperforms before and
after each intervention diet and 6 months after the last intervention.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |